Skip to content

Trial Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.



ACTRN/NCT /ethics:


Scientific title:

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeSolid Tumor
Trial TypeInterventional
PhasePhase I
Age Range18 Years and older  
Tumour Stream -
Cancer Stage-
Anticipated Start Date2022-08-25
Anticipated End Date2025-08-05

Participating Hospitals

HospitalIcon Cancer Centre - Tennyson and Windsor Garden
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorFrancis Parnis
Recruitment StatusRecruiting